Rodman & Renshaw assumed coverage on shares of Female Health Company (The) (NASDAQ:FHCO) in a report issued on Wednesday, Marketbeat reports. The firm issued a buy rating and a $5.00 price objective on the stock.

Female Health Company (NASDAQ:FHCO) opened at 1.27 on Wednesday. Female Health Company has a 52-week low of $0.72 and a 52-week high of $1.65. The stock has a 50 day moving average price of $1.14 and a 200 day moving average price of $1.06. The company’s market capitalization is $39.80 million.

Female Health Company (The) (NASDAQ:FHCO) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million for the quarter. Female Health Company (The) had a negative return on equity of 12.51% and a negative net margin of 29.27%. Analysts anticipate that Female Health Company will post $0.15 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Rodman & Renshaw Initiates Coverage on Female Health Company (The) (NASDAQ:FHCO)” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at

In other Female Health Company (The) news, Director Elgar Peerschke acquired 50,000 shares of Female Health Company (The) stock in a transaction that occurred on Friday, June 9th. The shares were bought at an average price of $1.25 per share, with a total value of $62,500.00. Following the completion of the purchase, the director now directly owns 145,520 shares in the company, valued at approximately $181,900. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Harry Fisch acquired 24,750 shares of Female Health Company (The) stock in a transaction that occurred on Monday, May 22nd. The stock was acquired at an average cost of $1.02 per share, for a total transaction of $25,245.00. The disclosure for this purchase can be found here. Insiders have bought 230,569 shares of company stock valued at $266,867 over the last quarter. Company insiders own 10.90% of the company’s stock.

Female Health Company (The) Company Profile

The Female Health Company is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.

Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.